Spotlight Stock,Trends & Articles Entheon Biomedical to Execute a Non-Brokered Private Placement Funding By Dennis Mutua April 07, 2022 Biotechnology company focused on research and development of psychedelic medicines to address addictions disorders and mental illnesses Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) announced that it will be moving forward w...
Featured,Spotlight Stock,Trends & Articles Field Trip Receives US Patent for Novel Psychedelic Molecule FT-104 By Dennis Mutua April 06, 2022 Biotechnology company specializing on developing and delivering technology enabled psychedelic therapies Field Trip Health Ltd. (NASDAQ: FTRP) (TSX: FTRP) has been granted a patent for claims linked to FT-104, the company’s firs...
Spotlight Stock,Trends & Articles MindMed’s CFO David Guebert Set to Leave the Company This Week By Dennis Mutua March 29, 2022 David Guebert, the chief financial officer of Mindmed Inc. (NASDAQ: MNMD) (NEO: MMED) is set to retire from his position at the last day of this month i.e. March 31st. This announcement was made by the company’s director and chi...
Featured,Trends & Articles Third City in Michigan Decriminalizes Natural Psychedelics By Dennis Mutua March 25, 2022 On March 22, Hazel Park City Council, voted by a unanimous decision to decriminalize use of psilocybin mushrooms and other entheogenic plants across the city. Hazel Park becomes the third city in Michigan State to take such a move...
Featured,Spotlight Stock,Trends & Articles Mycotopia Therapies Partners With HAVN and Ei. Ventures to Join Medicinal Mushroom Market By Dennis Mutua March 23, 2022 Biotechnology company providing psychedelic-therapies through technology-focused, data driven and medical based solutions for addictions and mental health patients Mycotopia Therapies Inc. (OTCMKTS: TPIA) is seeking to enter the $...
Featured,Spotlight Stock,Trends & Articles Numinus Granted New Biosecurity License to Expand Psilocybin Research By Dennis Mutua March 15, 2022 Mental health and wellness company focusing on evidence-based accessible psychedelic assisted psychotherapy to patients Numinus Wellness Inc. (TSE: NUMI) (OTCMKTS: NUMIF) announced having received a new federal license which allow...
Featured,Spotlight Stock,Trends & Articles Washington Legislature Approves $200,000 Budget for Psychedelic Research Funding By Dennis Mutua March 14, 2022 Late last week, the Washington State legislature forwarded a bill to the office of the governor which included a proposal to directly provide $200,000 to fund an emerging workgroup to conduct studies on the possibilities of legali...
Spotlight Stock,Trends & Articles Numinus Granted Approval by Health Canada to Study Ayahuasca and San Pedro at its Research Facility By Dennis Mutua March 10, 2022 Mental health and wellness company specializing on evidence-based accessible psychedelic assisted psychotherapy to treat addictions and mental conditions Numinus Wellness Inc. (TSE: NUMI) (OTCQX: NUMIF) announced having being gran...